NO329958B1 - Anvendelse av en immunogen mengde av OspA-lipoprotein fra Piscirickettsia salmonis, OspA-antigen, og immunogene promiskuose TCE i et OspA-kimaert fusjonsprotein, for fremstilling av medikamenter, og immunologisk in vitro-fremgangsmate for deteksjon av humoralt antistoff mot OspA eller P. salmonis. - Google Patents

Anvendelse av en immunogen mengde av OspA-lipoprotein fra Piscirickettsia salmonis, OspA-antigen, og immunogene promiskuose TCE i et OspA-kimaert fusjonsprotein, for fremstilling av medikamenter, og immunologisk in vitro-fremgangsmate for deteksjon av humoralt antistoff mot OspA eller P. salmonis.

Info

Publication number
NO329958B1
NO329958B1 NO20004637A NO20004637A NO329958B1 NO 329958 B1 NO329958 B1 NO 329958B1 NO 20004637 A NO20004637 A NO 20004637A NO 20004637 A NO20004637 A NO 20004637A NO 329958 B1 NO329958 B1 NO 329958B1
Authority
NO
Norway
Prior art keywords
ospa
immunogenic
tce
promiscuous
vitro
Prior art date
Application number
NO20004637A
Other languages
English (en)
Other versions
NO20004637L (no
NO20004637D0 (no
Inventor
William W Kay
Michael A Kuzyk
Jan Burian
Julian C Thornton
Original Assignee
Pfizer Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25681189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329958(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA002281913A external-priority patent/CA2281913A1/en
Application filed by Pfizer Canada Inc filed Critical Pfizer Canada Inc
Publication of NO20004637D0 publication Critical patent/NO20004637D0/no
Publication of NO20004637L publication Critical patent/NO20004637L/no
Publication of NO329958B1 publication Critical patent/NO329958B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20004637A 1999-09-17 2000-09-15 Anvendelse av en immunogen mengde av OspA-lipoprotein fra Piscirickettsia salmonis, OspA-antigen, og immunogene promiskuose TCE i et OspA-kimaert fusjonsprotein, for fremstilling av medikamenter, og immunologisk in vitro-fremgangsmate for deteksjon av humoralt antistoff mot OspA eller P. salmonis. NO329958B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15443799P 1999-09-17 1999-09-17
CA002281913A CA2281913A1 (en) 1999-09-17 1999-09-17 A vaccine against piscirickettsia salmonis based on a recombinant 17 kd protein

Publications (3)

Publication Number Publication Date
NO20004637D0 NO20004637D0 (no) 2000-09-15
NO20004637L NO20004637L (no) 2001-03-19
NO329958B1 true NO329958B1 (no) 2011-01-31

Family

ID=25681189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004637A NO329958B1 (no) 1999-09-17 2000-09-15 Anvendelse av en immunogen mengde av OspA-lipoprotein fra Piscirickettsia salmonis, OspA-antigen, og immunogene promiskuose TCE i et OspA-kimaert fusjonsprotein, for fremstilling av medikamenter, og immunologisk in vitro-fremgangsmate for deteksjon av humoralt antistoff mot OspA eller P. salmonis.

Country Status (2)

Country Link
GB (1) GB2356632B (no)
NO (1) NO329958B1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001240791A1 (en) 2000-03-11 2001-09-24 Novartis Ag Sequence
PT1282710E (pt) 2000-03-11 2008-04-08 Novartis Ag Vacina contra a piscirickettsia salmonis para peixes
US7811583B2 (en) 2007-12-19 2010-10-12 Intervet International B.V. Antigens and vaccines against Piscirickettsia salmonis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0877085A1 (en) * 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines
US5736347A (en) * 1992-01-17 1998-04-07 The United States Of America As Represented By The Department Of Health And Human Resources Nucleic acids of Rochalimaea henselae and methods and compositions for diagnosing Rochalimaea henselae and Rochalimaea quintana infection
SE515216C2 (sv) * 1998-02-20 2001-07-02 Kenneth Nilsson Ny peptid, diagnostiskt reagens och kit för detektion av rickettsioser
AU3005499A (en) * 1998-03-16 1999-10-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties

Also Published As

Publication number Publication date
NO20004637L (no) 2001-03-19
GB2356632B (en) 2004-07-21
NO20004637D0 (no) 2000-09-15
GB0022825D0 (en) 2000-11-01
GB2356632A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
HK1083026A1 (en) Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2012149045A3 (en) Liposomal formulations
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2002024739A3 (en) Spas-1 cancer antigen
AU2001246909A1 (en) Tube for medical care and method for preparing the same
DE60042816D1 (de) T-helferzellen-epitope
NO329958B1 (no) Anvendelse av en immunogen mengde av OspA-lipoprotein fra Piscirickettsia salmonis, OspA-antigen, og immunogene promiskuose TCE i et OspA-kimaert fusjonsprotein, for fremstilling av medikamenter, og immunologisk in vitro-fremgangsmate for deteksjon av humoralt antistoff mot OspA eller P. salmonis.
ZA200203294B (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them.
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20023249L (no) Nye substituerte pyrazolo(4,3-e)diazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
HUP0201731A3 (en) Tetradeca-8,10-dienals, the method of preparation thereof and their use as sexual attractans for leafminer moths
WO1999058563A3 (en) Moraxella catharralis proteins
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
MXPA01011611A (es) Derivados de espiroimidazolidina, su prepracion, su uso y preparaciones farmaceuticas que los comprenden.
NO963129L (no) Nye leukotrien-B4-derivater, fremgangsmåte for fremstilling derav og anvendelse derav som legemidler
AU6808794A (en) cs31a protein capsule subunit modified by at least one heterologous peptide, cs31a protein capsule comprising said subunit, micro-organisms having such subunits on their outer membrane, and methods for preparing and using same
WO2004001425A3 (en) Mhc class ii haplotype specific immunodominancy of peptides derived from rsv fusion (f) and attachement (g) proteins
WO2002090383A3 (en) M. catarrhalis antigens
AU2001282503A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
Robinson et al. Immunisation myths and misconceptions.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ZOETIS CANADA, CA

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: FVG LTD, GB

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

MM1K Lapsed by not paying the annual fees